ACCREDITATION
AACE Annual Meeting
Continuing Medical Education Information
Event start date: 05/15/2025
Credit claim deadline: 12/31/2025
Statement of Need
AACE 2025 Annual Meeting is designed to provide Endocrinologists and Patient Care Team Members with practical applications of the most current practice guidance and the latest scientific discovery in the diagnosis and treatment for endocrine-related disorders.
Target Audience
This program is intended for medical professionals from the field of clinical endocrinology at all stages in their career including clinical endocrinologists, primary care physicians, physician assistants, nurse practitioners, nurses, pharmacists, registered dietitians, medical students, residents, and fellows in training.
Learning Objectives
By the end of the meeting, participants will be able to:
- Discuss the latest scientific and clinical discoveries in the field of endocrinology, diabetes, and metabolism.
- Apply newfound knowledge to diagnosis and management for improved patient outcomes.
- Assess the potential applications of emerging scientific advances that affect the practice of endocrinology.
- Empower participants to educate their patients regarding clinical treatment options.
Accreditation and Designation Statements
ACCME
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this “Other” (live and on demand) for a maximum of 51.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
Provider approved by the California Board of Registered Nursing, Provider Number 17762, for 51.75 contact hours.
ABOM
Applicants for certification through the American Board of Obesity Medicine (ABOM) may claim up to 9 Group Two CME credits toward the ABOM application requirement for attending all sessions in the obesity track.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 51.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.
Please allow two weeks for MOC points to appear within your account on the ABIM website. Participation information will be shared.
Disclosure and Conflicts of Interest Policy
The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.
Commercial Support
This activity is supported by educational grants from the following:
- Dexcom, Inc.
- Abbott Diabetes Care
- Medtronic, Inc
- Amgen
- Insulet Corporation
- Merck
Planning Committee Disclosures
Planner Name
Isaacs, Diana
Ineligible Company
(1) Abbott, Dexcom, Medtronic, Insulet, Lilly, Novo Nordisk, Cequr, Sanofi (2) Lilly, Sanofi, Medtronic, Lifescan, Sequel, Sanofi
Relevant Financial Relationship
(1) Speakers Bureau; (2) Advisory Board
Planner Name
Kotwal, Anupam
Ineligible Company
Interpace Diagnostica; Immunovant
Relevant Financial Relationship
Consultant
Planner Name
Low Wang, Cecilia
Ineligible Company
Dexcom, Virta Health
Relevant Financial Relationship
Research funding
Planner Name
Sadhu, Archana
Ineligible Company
Abbott
Relevant Financial Relationship
Consultant
Planner Name
Schulman-Rosenbaum, Rifka
Ineligible Company
Sanofi
Relevant Financial Relationship
Publication Support
All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Faculty Disclosures
View Faculty Disclosures
All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Reviewers
Name
Kotwal, Anupam
Ineligible Company
Interpace Diagnostica; Immunovant
Relationship
Consultant
All of the relevant financial relationships listed for these individuals have been mitigated. All other reviewers for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
